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Background: Anaemia of chronic kidney disease increases the risk of death and adverse events, but can be
managed using erythropoiesis stimulating agents (ESAs). However, recent evidence suggests that targeting a higher
haemoglobin concentration ([Hb]) increases mortality risk, and both higher [Hb] targets and ESA doses have been
implicated. Nonetheless, a causative role has not been demonstrated, and this potential relationship requires further
appraisal in such a complex patient group.
Methods: The relationship between the haematopoietic response to ESAs and patient survival in 302 stable,
prevalent dialysis patients was explored in a prospective, single-centre study. Clinical and laboratory parameters
influencing mortality and ESA resistance were analysed. Patients were stratified into 5 groups, according to their
[Hb] and ESA dosage, and were followed for 2 years.
Results: Little difference in co-morbidities between groups was identified. 73 patients died and 36 were
transplanted. Initial analysis suggested a direct relationship between mortality and ESA dosage. However, Cox
proportional hazards multivariate analysis demonstrated mortality risk was associated only with age (adjusted HR
per year: 1.061, 95% CI 1.031-1.092), dialysis duration (adjusted HR: 1.010, 95% CI 1.004-1.016), peripheral vascular
disease (adjusted HR: 1.967, 95% CI 1.083-3.576) and CRP (adjusted HR: 1.024, 95% CI 1.011-1.039). Mortality was
increased in patients poorly responsive to ESAs (55.5%).
Conclusion: ESA dose does not appear to contribute substantially to mortality risk in dialysis patients. Instead, age
and co-morbidities appear to be the critical determinants. A poor response to ESAs is a marker of overall poor
health status.
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Erythropoiesis stimulating agents (ESAs) have been used
to raise and maintain haemoglobin concentrations ([Hb])
since a link between anaemia, impaired quality of life, and
adverse outcomes in patients with chronic kidney disease
(CKD) was first suggested [1-3]. However, more recent
studies have suggested that higher Hb targets (≥120 g/L)
may paradoxically increase the rate of adverse vascular
events [4-6]. In one recent randomised controlled trial in* Correspondence: lawrence.mcmahon@monash.edu
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reproduction in any medium, provided the ornon dialysis-dependent CKD patients with diabetes and
moderate anaemia (TREAT), the use of darbepoetin-alfa
failed to reduce the risk of the composite end point of
death and non-fatal cardiovascular events. More worry-
ingly, it was also associated with an increased risk of stroke
[7].
The mechanism for such an increase in the adverse event
rate remains unclear, with suspicion falling on both the tar-
geted [Hb] and ESAs themselves as causative agents [8].
The upper end of the target [Hb] range has been reduced
in many countries; but a number of studies have also sug-
gested that perhaps the absolute [Hb] is less important
than the ESA dose [9-11]. However, it is important toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mine the true relationship has been limited by inherent
trial design [12]. This fact was highlighted by an additional
recent study, which found that after adjusting for multiple
factors (including ESA dose), mortality actually reduced
with increasing [Hb] in a prospectively followed incident
cohort of Spanish haemodialysis patients [13].
This study was therefore designed to compare different
ESA responsiveness patterns in a single-center cohort of
prevalent dialysis patients, and to establish which factors
influenced mortality. Whilst recognizing the inherent lim-
itations of observational studies, we were able to explore
more fully the relationship between [Hb], ESA resistance,
and patient survival, incorporating the interplay of various
clinical co-morbidities and laboratory parameters which




This was a single-centre, prospective observational cohort
study, approved by the Royal Melbourne Hospital Research
and Ethics Committee. All prevalent dialysis-dependent
patients (n=596) were screened for eligibility between
March and June 2003. Patients with a stable [Hb] (±5.0 g/L),
no hospitalizations and an unchanged ESA dose (each for
at least the prior 3 months), who were able to give
informed consent were included.
ESA dose was expressed as IU/kg/week (darbepoetin alfa
doses were converted as μg/kg/wk x 200). Patients were
allocated to 1 of 5 groups (4 with [Hb] >110 g/L) accord-
ing to ESA responsiveness as follows: NE (No ESA),
patients with a [Hb] ≥110 g/L and not requiring ESA; LE
(Low ESA), requiring minimal ESA (<50 IU/kg/week)
with a [Hb] ≥110 g/L; GR (Good Responders), requiring
50–200 IU/kg/week to maintain a [Hb] ≥110 g/L; HE
(High ESA), requiring >200 IU/kg/week to maintain a
[Hb] ≥110 g/L; PR (Poor Responders), requiring
>200 IU/kg/week, yet [Hb] <110 g/L (Figure 1).
Clinical, demographic and laboratory assessments
Data collected at baseline included age, sex, aetiology of
CKD, blood pressure, co-morbidities (coronary artery
disease and/or congestive heart failure, peripheral vascu-
lar disease, prior cerebrovascular event, chronic airflow
obstruction, treated hypertension and dyslipidaemia),
body mass index (BMI), dialysis mode, and duration of
end stage kidney disease (ESKD), including duration of
dialysis and/or past renal transplantation.
Laboratory tests at baseline, 1 year and 2 years included
[Hb], albumin, iron studies (ferritin and transferrin satur-
ation, TSAT), and C-reactive protein (CRP). Serum vitamin
B12, folate, and parathyroid hormone (PTH) were mea-
sured at baseline. Dose of dialysis for haemodialysis (HD)patients included both Kt/V and urea reduction ratio
(URR); and for peritoneal dialysis (PD) patients a standard
adequacy study was performed measuring total creatinine
clearance and residual renal function. Changes in dialysis
modality during the study were recorded.
Statistical analysis
All analyses were performed by SPSS 18 (Chicago, Il,
USA). This was an exploratory analysis examining the rela-
tionship between [Hb] and ESA dosage with particular re-
gard to ESA dose (split into three groups, high, normal
and low) and outcome, in patients with a similar [Hb]. The
PR Group was added as control to exclude the effects of
low [Hb] and high ESA. Data are displayed as mean±
standard deviation (SD), or median and IQR according to
distribution and skew. Categorical variables were compared
by the Chi-square test. Normally-distributed continuous
variables were compared by ANOVA and for comparison
of non-parametric continuous data Kruskal-Wallis test was
applied. In a particular ESA category the difference be-
tween observations taken at baseline, 1 year or 2 years was
assessed by t-test for normally distributed data, and for
non-parametric data the Wilcoxon signed rank test was
used. Kaplan-Meier survival curves were generated with
patients censored if transplanted.
To compare the risk of mortality across groups the Cox
multivariate proportional hazards model was used with
adjustments for factors which could potentially alter the
risk of mortality. The forward likelihood ratio (LR) method
was used to estimate the influence of various covariates on
ESA category-specific mortality risk. The covariates
included ESA category followed by age, sex, cardiovascular
disease, peripheral vascular disease (PVD), blood pressure,
obesity, chronic airflow obstruction, cause of renal failure,
dyslipidaemia, previous transplant, duration of ESKD, dia-
lysis duration, dialysis modality, residual renal function,
and the following baseline data: [Hb], ESA dosage, serum
albumin, PTH, iron studies, CRP, and alkaline phosphatase
concentrations. For model consistency, obesity was
regarded as a categorical variable with a BMI cut-off at
30 g/m2, and the mode of dialysis was classified as HD or
PD. The design of the study restricted having data on all
these covariates at the time of death or follow-up. The pri-
mary outcome measure was death at 2 years. Secondary
outcome measures included transplantation, change in
[Hb] and change in ESA requirements.
Results
Of 596 stable patients screened, 302 were enrolled and fol-
lowed for 2 years (Figure 1). The most common cause of
CKD was glomerulonephritis (40%) followed by diabetic
nephropathy (18.5%). The highest percentage of patients
with adult polycystic kidney disease was in the NE Group


































Figure 1 Patient selection, categorization and outcome. NE: No ESA; LE: Low ESA; GR: Good Responders; HE: High ESA; PR: Poor Responders.
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sive, 34.8% had known coronary artery disease, 23.3% had
peripheral vascular and 12.7% cerebrovascular disease. The
median dialysis duration was 33 months. Only 6% had a
BMI over 30. Overall, the severity of clinical co-morbidities
differed little between groups. There were 244 haemodialy-
sis (HD) and 58 peritoneal dialysis (PD) patients. Ten
patients switched from PD to HD during the study (3 from
NE, 4 from LE and 3 from GR Group). Most PD patientsTable 1 Overall and group demographic and clinical data at s
Overall NE
Age, years * 60 ± 14 53 ± 14
Females, n (%) 109 (36.1) 6 (17.1)
Diabetes, n (%) 56 (18.5) 7 (20.0)
CAD, n (%) 108 (35.8) 9 (25.7)
HT, n (%) * 267 (88.4) 26 (74.3)
PVD, n (%) 70 (23.3) 4 (11.4)
CVA, n (%) * 38 (12.7) 2 (5.7)
COPD, n (%) 29 (9.6) 4 (11.4)
Dyslipidemia, n (%) 118 (39.1) 8 (22.9)
BMI kg/m2 * 25.9 ± 5.6 27.1 ± 7.7
Obesity, n (%) * 18 (6) 3 (8.6)
Previous transplant, n (%)* 10 (28.6) 4 (8.3)
HD, n (%) * 244 (80.8) 24 (68.6)
Duration of ESKD (months) 34 (18–60) 49 (28–111)
Time on dialysis (months) 33 (18–58) 41 (27–88)
BMI: body mass index, CAD: coronary artery disease, HT: hypertension, PVD: periphe
obstructive pulmonary disease, Obesity: BMI> 30 kg/m2, HD: haemodialysis, ESKD: e
displayed as mean ± SD, n (%), or median (25th-75th quartile), as indicated.had significant residual renal function (mean creatinine
clearance 16.9 L/wk), which was considered negligible in
HD patients (urinary output <300 mL per day). There was
no difference between groups in the duration of dialysis or
ESKD, nor in the dose of dialysis received between groups
(Table 1).
The NE Group was youngest, had the highest [Hb], and
lowest prevalence of hypertension; whereas patients in the
PR Group were older, more hypertensive, likely to betudy entry
LE GR HE PR
57 ± 14 60 ± 15 64 ±12 69 ± 11
16 (33.3) 61 (38.1) 17 (41.5) 9 (50)
15 (31.0) 23 (14.3) 8 (16.3) 3 (16.7)
17 (35.4) 56 (35) 18 (43.9) 8 (44.4)
44 (91.7) 146 (91.3) 34 (82.9) 17 (94.4)
16 (33.3) 33 (20.6) 11 (26.8) 6 (33.3)
6 (12.5) 17 (10.6) 12 (29.3) 1 (5.6)
3 (6.3) 13 (8.1) 7 (17.1) 2 (11.1)
24 (50) 60 (37.5) 17 (41.5) 9 (50)
27.5 ± 5.9 25.1 ± 4.7 24.6 ± 4.4 28.9 ± 6.9
6 (12.5) 6 (3.8) 0 3 (16.7)
19 (11.9) 5 (12.2) 1 (5.6) 39 (12.9)
30 (62.5) 135 (84.4) 38 (92.7) 17 (94.4)
26 (15–56) 34 (17–60) 31 (19–54) 31 (23–58)
36 (18–66) 37 (22–59) 31 (23–58) 35 (18–61)
ral vascular disease, CVA: past cerebrovascular accident, COPD: chronic
nd stage kidney disease *: p< 0.05 for between-group analysis. Data are
Table 2 Laboratory parameters at the baseline (and end) of study as indicated
Variable Time NE LE GR HE PR
Ferritin (μg/L) Initial * 202 (80–296) 429 (228–607) 347 (235–539) 469 (206–640) 516 (353–772)
At 2 years * 181 (57–222) 285 (190–422) 389 (230–423) 288 (252–384) 239 (183–284)
TSAT (%) Initial * 25 (20–38) 25 (19–37) 25 (20–33) 24 (19-27) 19 (16-23)
At 2 years 26 (16–31) 26 (22–32) 22 (19-28) 22 (18-27) 17 (15-24)
CRP (mg/dL) Initial * 4 (2-11) 6.5 (3.8-15.5) 5 (2-10) 8 (3-30) 17 (12-23)
At 2 years 4 (2-9) 6.5 (3-14) 5 (2-10) 4 (2–13.5) 16 (5–37)
Albumin (g/L) Initial * 38 ± 4 38± 5 37± 4 37± 4 34 ± 4
At 2 years 37 ± 5 38± 5 40± 3 39± 4 37 ± 6
PTH (pmol/L) Initial 23 (11–49) 23 (10–47) 22 (11–54) 28 (14–57) 44 (25–68)
Vitamin B12 (pmol/L) Initial 317 (237–488) 396 (290–487) 373 (282–514) 362 (246–515.7) 274(217–454)
Folate (nmol/L) Initial 42 (12–45) 19 (9–45) 35 (13–45) 45 (13–45) 39 (17–45)
Abbreviations as per text. Values given include median (and IQR), or mean ± SD. Initial values and those after 2 years are shown. *: p< 0.05 for between-group
analysis at time point indicated.
McMahon et al. BMC Nephrology 2012, 13:40 Page 4 of 8
http://www.biomedcentral.com/1471-2369/13/40obese, and were less likely to have received a previous kid-
ney transplant. The NE Group also had a higher baseline
[Hb] and lower serum ferritin compared to other groups.
In contrast, the PR Group had lower baseline [Hb] and
serum albumin, and higher ferritin and CRP (Table 2).
Of the 73 (24.2%) deaths in 2 years, the PR Group had
the highest death rate (56%) followed by the HE, GR, NE
and LE Groups respectively (Figure 1). At baseline and
after 2 years, HD patients received a higher ESA dosage
compared to PD patients despite no difference in age,
BMI, haematinics (iron studies, vitamin B12 and folate),
CRP or PTH levels. Death rates did not differ between HD
and PD patients (23.9% vs. 22.4%, p=0.48). The most com-
mon cause of death was a cardiovascular event (45.2%), fol-
lowed by sepsis (17.8%). During the study period, 36
patients (11.9%) received a kidney transplant. The NE and
LE Groups had the highest rates of transplantation (≥20%),
while none of the PR patients were transplanted (Figure 1).
There was no significant difference between baseline and
2-year [Hb] within or between groups, except in the GR
Group (mean [Hb] 123 g/L versus 120, Figure 2). Survivors
in the PR Group had a higher mean [Hb] at study end, al-
though changes were not statistically significant (Figure 2).
ESA requirements increased in both NE and LE Groups,
and decreased in the HE Group; however the PR Group
recorded the highest ESA dosage both initially and at
2 years (Figure 2, Table 2).
Over the 2-year period, the [Hb] remained relatively un-
changed. The ESA dosage increased significantly in the
NE, GR and HE Groups; however the PR Group remained
on the highest doses (Figure 2). The poor hematopoietic
response to ESAs persisted in the PR Group throughout
the study and, in 2 years, only 3 of 18 patients had achieved
a [Hb] >110 g/L.
The Kaplan-Meier survival analysis revealed a decreased
cumulative survival in the PR Group compared to others,and suggested survival correlated with specified group (Fig-
ure 3). A Cox multivariate hazards analysis was under-
taken, adjusted for all variables but specifically for age,
CRP, duration on dialysis and PVD. Where death occurred
the last known measure was carried forward to 2 years.
The apparent increase in mortality risk in the PR group
was found to be statistically associated with age, baseline
CRP concentration, duration on dialysis and presence of
PVD. In this model, [Hb], ESA dosage and, importantly,
the assigned group category were not significant, suggest-
ing they were not independent variables for mortality risk
(Table 3, Figure 3). These data suggest that for every year
increase in age, the 2-year mortality risk increased by ap-
proximately 6%, and by 2.5% for every 1 mg/dL increase in
CRP. Additionally, each month on dialysis conferred a 1%
increment in hazard ratio, and the presence of PVD
doubled that risk (Table 3). Similarly, compared to the
patients receiving low dose ESA (LE+GR Groups) those
on high dose ESA (HE+PR Groups) had a decreased 2-
year cumulative survival. This increased mortality risk was
independently associated with age, baseline CRP, duration
of dialysis and PVD, but not ESA dose. Even after exclud-
ing the PR Group from the model, the same variables were
retained as significant within the model, but serum albu-
min became a significant contributor to the risk (Table 3).
Discussion
Findings from this study indicate that mortality in stable
dialysis patients, when categorized by ESA dosage and
[Hb], is related primarily to age, CRP, dialysis duration and
peripheral vascular disease (PVD). The apparent associ-
ation between mortality and higher ESA doses demon-
strated in the Kaplan Meier regression curves (Figure 3),
and which has also been observed in interventional studies
[4-7,14] proved to be spurious as no direct relationship















Cumulative probability of survival
Figure 3 Kaplan-Meier survival curve for all groups during the
2-year period. Group coding as per Figure 1. P = 0.002.
Figure 2 Hemoglobin concentration and ESA dosage at
baseline (white) and 2 years (black). Group coding as per
Figure 1. Significant differences were observed only in the GR
Group. ESA dosage increased in the NE and LE Groups and
decreased in the HE Group *: p< 0.05.
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PR Group (with the highest mortality risk, the highest ESA
dosage and the lowest [Hb]) was included or not.
Age is known to be an independent and powerful, if un-
avoidable, predictor of death for patients with ESKD, and
is also significantly associated with PVD especially amongst
non-diabetic CKD patients [15-17]. Peripheral vascular dis-
ease is itself an independent determinant of all-cause mor-
tality and cardiovascular events in ESKD. The presence of
PVD in haemodialysis patients doubles the risk of
hospitalization for major cardiovascular events, and
increases the risk for all-cause hospitalizations by 19%
[18,19]. Chronic inflammation is also associated with
increased morbidity and mortality in patients receiving dia-
lysis, and the inter-relationship between inflammation, in-
adequate nutrition and a poor response to ESA is well
recognised [20-22]. Our study thus adds weight to the hy-
pothesis that it is these well-identified risk factors of age,
dialysis duration, vascular disease and inflammation which
appear to determine mortality outcomes in a dialysiscohort. In contrast, hyporesponsiveness to ESAs appears to
be simply a surrogate marker of poor underlying overall
health.
The recently published ANSWER Study [13] comprised
incident haemodialysis patients, whereas all patients in the
current study were prevalent dialysis patients, many of
whom had been on dialysis for over four years, and almost
20% of whom were on peritoneal dialysis. However,
patients in each study exhibited substantial cardiovascular
co-morbidity, and findings were similar, except that the
ANSWER Study specified one ESA dosage (between 8000
and 16000 IU/week) as an independent predictor of mor-
tality. However, higher ESA doses were not similarly identi-
fied, and it is difficult to reconcile this result with anything
other than a statistical anomaly. Other factors potentially
contributing to poor ESA responsiveness in our study, in-
cluding dialysis dose, hematinic studies and parathyroid
hormone levels, were specifically looked for and found not
to be associated with mortality. Such variables also did not
differ between groups. Our findings corroborate the find-
ings of the ANSWER Study, in that neither the high ESA
dosage nor [Hb] directly related to mortality in this patient
group.
Is it possible to reconcile these findings with the larger
randomized controlled trials (RCT) which have highlighted
an apparent association between a reduced hematopoietic
response to ESA and greater risk of an adverse outcome?
Unfortunately, further analysis from these studies is limited
by lack of data on other issues relating to individual
patients’ health status, many of which can influence
achieved [Hb] and ESA dose [4-7,14,23-26]. Nonetheless,
relative differences between these interventional studies,
including the nature of the patient cohorts, outcomes and
endpoints, and the variable dose of ESAs required,
Table 3 Cox proportional hazards model
Variable Adjusted mortality hazardsHR (95%CI)
All patients(n= 203) Excluding PR Group(n= 185)
Age (per year) 1.05 (1.02-1.08)* 1.04 (1.01-1.08)*
CRP (per unit rise) 1.02 (1.01-1.03)* 1.02 (1.01-1.03)*
Duration on dialysis (per month) 1.01 (1.00-1.01)* 1.01 (1.00-1.01)*
Peripheral vascular disease 1.75 (1.00-3.04)* 1.80 (0.97-3.25)
ESA dose 1.001 (0.996-1.006) 1.000 (0.997-1.004)
[Hb] 1.008 (0.962-1.056) 0.998 (0.947-1.052)
LE Group 0.37 (0.08-1.68) 0.46 (0.10-2.23)
GR Group 1.10 (0.38-3.17) 1.39 (0.41-4.75)
HE Group 0.96 (0.30-3.11) 1.07 (0.22-5.29)
PR Group 1.58 (0.49-5.09) -
Test of model assumption X(4)
2 = 1.00, p = 0.910 X(4)
2 = 0.33, p = 0.988
Adjusted hazard ratios of mortality for all patients (n = 203) and without the PR Group (n = 185).
A test of the proportional hazards assumption was undertaken and the models were deemed not to violate any assumption. *p< 0.05.
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particular, patients with greater cardiovascular co-
morbidity generally had a higher mortality rate and used
substantially more quantities of a given ESA to achieve the
target [Hb]. As stated, none of these RCTs could demon-
strate more than an associative relationship between ESA
dose and mortality, and the observational nature of our
study similarly precludes causation. However, the findings
do suggest caution in establishing an overly simplistic ex-
planation between death and the use of ESAs.
Thrombosis is a recognized and concerning complica-
tion of ESA treatment. It was first identified as a risk factor
for access thrombosis in the Canadian placebo-controlled
study [27], and subsequently confirmed in the Normal
Hematocrit Study [6], amongst others. It was also recently
confirmed as a risk factor for (mainly) non-haemorrhagic
stroke in the TREAT Study [7]. Thrombosis itself was not
studied as an endpoint in the current study and it might
have been useful in determining the influence of ESA dose
and/or [Hb] in vascular access thrombosis. Whether it
would have been relevant in assessing thrombotic stroke
risk is arguable. Although stroke was clearly evident as a
risk factor in the TREAT Study, it took 4000 diabetic
patients, mostly with known cardiovascular co-morbidities,
for it to be identified as such. A recent placebo-controlled
study of ESA use in acute ischemic stroke corroborated
these findings [28]. It therefore remains uncertain whether
ESA dose and/or Hb are associated with thrombotic stroke
in a dose and/or concentration-dependent fashion, al-
though ESA use itself must be accepted as inherently
thrombogenic.
The [Hb] used to define target groups was higher than
current targets [29], but was within standard parameters
when the study was performed. We believe this is one of
the study’s strengths, since any direct effect of ESAs or[Hb] should have been accentuated by such a strategy. In
addition, the mortality rate for the group overall did not
appear materially different to previously reported studies,
suggesting that the target [Hb] issue was not of great rele-
vance. Furthermore, the cause of death showed no statis-
tical differences between groups, although this could well
relate to the limited numbers.
Despite a higher mean [Hb] (134 g/L) in the NE Group,
mortality was no higher, and possibly less, compared with
other groups. At least one recent report suggests that a
naturally-occurring [Hb], even at physiological concentra-
tions, is not associated with a higher mortality risk [30].
These findings are also supported by our data. The two-
year mortality was highest in the PR group. After adjusting
for risk factors, it became evident that these patients were
older, had been on dialysis longer, had worse PVD and a
higher CRP. Such a high mortality index is difficult to re-
solve with the small numbers of patients in this group –
only eight patients were left at study completion. However,
even when the PR group was excluded from the analysis,
the factors most clearly associated with mortality in groups
with comparable [Hb] but different ESA requirements
were unchanged.
There are acknowledged limitations of this study. First, it
is observational and limited conclusions only can be
drawn. Secondly, the sample size is relatively small, and
varied substantially between groups. The associated lack of
power might well have affected the capacity to discriminate
between individual group results. Thirdly, patients were
followed for only two years, with a relatively low mortality
index in most groups. However, the magnitude of the mor-
tality hazard risk associated with other co-morbidities
appears to be much larger than any ESA specific effect,
and since the results are consistent internally (between
groups) and externally (compared to other studies), we feel
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of the effects of ESA use in the dialysis population. Finally,
using only stable patients excluded many patients from the
cohort. Although adding to patient numbers and possibly
providing more comprehensive data, to have studied those
with cyclical or rising ESA needs would have required a
different approach to both baseline and follow-up.
Conclusion
In conclusion, in this prospective two-year cohort study,
age, underlying inflammation, duration of dialysis, and the
presence of PVD were significantly associated with mortal-
ity in dialysis patients. No independent association was
found with group, [Hb] or ESA dose, suggesting that co-
morbidity and age are the key players determining longev-
ity in this group of patients.
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